Ceftaroline is a next generation, broad spectrum, cephalosporin antibiotic that combines the advantage of an enhanced gram-positive spectrum, including bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA), with broad gram-negative activity.
The FDA recently granted ceftaroline fast track designation for the treatment of complicated skin and skin structure infections (cSSSI) caused by MRSA.
The phase II trial enrolled 100 patients with cSSSI and was conducted at more than 20 study sites worldwide. The objective of this trial was to investigate the efficacy and safety of ceftaroline versus standard therapy
“Given the urgent and unmet need for new antibiotics and the fast track designation recently granted ceftaroline, we are pleased to have completed this trial ahead of plan,” stated Dennis Podlesak, CEO of Cerexa.